Diffusion of robotics into clinical practice in the United States: process, patient safety, learning curves, and the public health

被引:42
|
作者
Mirheydar, Hossein S. [1 ,2 ]
Parsons, J. Kellogg [1 ,2 ]
机构
[1] Univ Calif San Diego, Div Urol Oncol, Moores UCSD Comprehens Canc Ctr, San Diego, CA 92103 USA
[2] Univ Calif San Diego, Div Urol, San Diego Vet Affairs Med Ctr, La Jolla, CA 92093 USA
关键词
Robotics; Prostatectomy; Partial nephrectomy; Cystectomy; Review; Urologic oncology; ASSISTED RADICAL PROSTATECTOMY; HIGH-VOLUME HOSPITALS; PARTIAL NEPHRECTOMY; LAPAROSCOPIC PROSTATECTOMY; PERIOPERATIVE OUTCOMES; PATHOLOGICAL OUTCOMES; COSTS; CYSTECTOMY; SURGERY; INSTITUTIONS;
D O I
10.1007/s00345-012-1015-x
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
Robotic technology disseminated into urological practice without robust comparative effectiveness data. To review the diffusion of robotic surgery into urological practice We performed a comprehensive literature review focusing on diffusion patterns, patient safety, learning curves, and comparative costs for robotic radical prostatectomy, partial nephrectomy, and radical cystectomy Robotic urologic surgery diffused in patterns typical of novel technology spreading among practicing surgeons. Robust evidence-based data comparing outcomes of robotic to open surgery were sparse. Although initial Level 3 evidence for robotic prostatectomy observed complication outcomes similar to open prostatectomy, subsequent population-based Level 2 evidence noted an increased prevalence of adverse patient safety events and genitourinary complications among robotic patients during the early years of diffusion. Level 2 evidence indicated comparable to improved patient safety outcomes for robotic compared to open partial nephrectomy and cystectomy. Learning curve recommendations for robotic urologic surgery have drawn exclusively on Level 4 evidence and subjective, non-validated metrics. The minimum number of cases required to achieve competency for robotic prostatectomy has increased to unrealistically high levels. Most comparative cost-analyses have demonstrated that robotic surgery is significantly more expensive than open or laparoscopic surgery. Evidence-based data are limited but suggest an increased prevalence of adverse patient safety events for robotic prostatectomy early in the national diffusion period. Learning curves for robotic urologic surgery are subjective and based on non-validated metrics. The urological community should develop rigorous, evidence-based processes by which future technological innovations may diffuse in an organized and safe manner.
引用
收藏
页码:455 / 461
页数:7
相关论文
共 50 条
  • [41] The Centers for Disease Control and Prevention's public health response to monitoring Tdap safety in pregnant women in the United States
    Moro, Pedro L.
    McNeil, Michael M.
    Sukumaran, Lakshmi
    Broder, Karen R.
    HUMAN VACCINES & IMMUNOTHERAPEUTICS, 2015, 11 (12) : 2872 - 2879
  • [42] Postmarket Safety Communication for Protection of Public Health: A Comparison of Regulatory Policy in Australia, Canada, the European Union, and the United States
    Bhasale, Alice L.
    Sarpatwari, Ameet
    De Bruin, Marie L.
    Lexchin, Joel
    Lopert, Ruth
    Bahri, Priya
    Mintzes, Barbara J.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2021, 109 (06) : 1424 - 1442
  • [43] Athletic trainers perceptions of health and safety best-practice policy & procedure implementation in United States Secondary Schools
    Scarneo-Miller, Samantha E.
    Kay, Melissa C.
    Register-Mihalik, Johna K.
    DiStefano, Lindsay J.
    QUALITATIVE RESEARCH IN SPORT EXERCISE AND HEALTH, 2021, 13 (02) : 250 - 266
  • [44] The Adoption of Low-Osmolar Contrast Agents in the United States: Historical Analysis of Health Policy and Clinical Practice
    Wilmot, Andrew
    Mehta, Neerav
    Jha, Saurabh
    AMERICAN JOURNAL OF ROENTGENOLOGY, 2012, 199 (05) : 1049 - 1053
  • [45] CLINICAL TRIAL LEARNING CURVES AFFECT OUTCOMES MEASUREMENT, PATIENT SAFETY AND TRIAL SUCCESS: CONTRIBUTING FACTORS AND A POTENTIAL SOLUTION IN CLINICAL TRIAL SIMULATION
    Spinner, D. S.
    Walter, J. W.
    Vazquez-Gragg, M.
    Bloise, T.
    Stafford-Smith, M.
    Faulkner, E. C.
    Taekman, J. M.
    VALUE IN HEALTH, 2011, 14 (03) : A24 - A25
  • [46] PHARMACIST-MANAGED PATIENT-CARE SERVICES AND PRESCRIPTIVE AUTHORITY IN THE UNITED-STATES-PUBLIC-HEALTH-SERVICE
    HERRIER, RN
    BOYCE, RW
    APGAR, DA
    HOSPITAL FORMULARY, 1990, 25 (01): : 67 - &
  • [47] Preliminary assessment of pediatric health care quality and patient safety in the United States using readily available administrative data
    McDonald, Kathryn M.
    Davies, Sheryl M.
    Haberland, Corinna A.
    Geppert, Jeffrey J.
    Ku, Amy
    Romano, Patrick S.
    PEDIATRICS, 2008, 122 (02) : E416 - E425
  • [49] Patient- and Clinician-Reported Outcomes for Tirbanibulin in Actinic Keratosis in Clinical Practice Across the United States (PROAK)
    Schlesinger, Todd
    Kircik, Leon
    Lebwohl, Mark
    Patel, Vishal A.
    Berman, Brian
    Bhatia, Neal
    Rigel, Darrell
    Armstrong, April
    Del Rosso, James
    Narayanan, Siva
    Koscielny, Volker
    Kasujee, Ismail
    JOURNAL OF DRUGS IN DERMATOLOGY, 2024, 23 (05) : 338 - 346
  • [50] Clinical outcomes and safety of the SpineJack vertebral augmentation system for the treatment of vertebral compression fractures in a United States patient population
    England, Ryan W.
    Gong, Anna
    Li, Taibo
    Botros, David
    Manupipatpong, Sasicha
    Pang, Sharon
    Hui, Ferdinand
    Khan, Majid
    JOURNAL OF CLINICAL NEUROSCIENCE, 2021, 89 : 237 - 242